VR Logo

Werewolf Therapeutics Inc. (HOWL) download report


Healthcare | Biotechnology & Pharma Research

Werewolf Therapeutics Inc. (HOWL) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer.

IPO Date: 30-Apr-2021

Founder, CEO, Pres, Sec. & Director: Dr. Daniel J. Hicklin Ph.D.

CFO, Treasurer & Assistant Sec.: Mr. Timothy W. Trost CPA

Listing: NASDAQ: HOWL

Country: United States

Headquarters: Cambridge, MA

Website: https://werewolftx.com

Key Facts

Market cap: $116.42 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $189.07 Mln

Cash: $143.71 Mln

Total Debt: $15.74 Mln

Insider's Holding: 20.51%

Liquidity: Low

52 Week range: $3.42 - 21.67

Shares outstanding: 27,654,200

Stock Performance

Time Period Werewolf Therapeutics (HOWL) S&P BSE Sensex S&P Small-Cap 600
YTD-65.91-8.99-19.23
1 month2.78-3.40-9.35
3 months-4.47-8.50-16.59
1 Year-74.470.89-17.36
3 Years--10.415.90
5 Years--11.435.77
10 Years--11.779.78
As on 30-Jun-2022